191 related articles for article (PubMed ID: 30344773)
1. Comparative cell biological study of in vitro antitumor and antimetastatic activity on melanoma cells of GnRH-III-containing conjugates modified with short-chain fatty acids.
Lajkó E; Spring S; Hegedüs R; Biri-Kovács B; Ingebrandt S; Mező G; Kőhidai L
Beilstein J Org Chem; 2018; 14():2495-2509. PubMed ID: 30344773
[No Abstract] [Full Text] [Related]
2. Drug targeting to decrease cardiotoxicity - determination of the cytotoxic effect of GnRH-based conjugates containing doxorubicin, daunorubicin and methotrexate on human cardiomyocytes and endothelial cells.
Polgár L; Lajkó E; Soós P; Láng O; Manea M; Merkely B; Mező G; Kőhidai L
Beilstein J Org Chem; 2018; 14():1583-1594. PubMed ID: 30013686
[No Abstract] [Full Text] [Related]
3. Apoptotic Effects of Drug Targeting Conjugates Containing Different GnRH Analogs on Colon Carcinoma Cells.
Lajkó E; Hegedüs R; Mező G; Kőhidai L
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500399
[TBL] [Abstract][Full Text] [Related]
4. Improved in vivo antitumor effect of a daunorubicin - GnRH-III bioconjugate modified by apoptosis inducing agent butyric acid on colorectal carcinoma bearing mice.
Kapuvári B; Hegedüs R; Schulcz Á; Manea M; Tóvári J; Gacs A; Vincze B; Mező G
Invest New Drugs; 2016 Aug; 34(4):416-23. PubMed ID: 27146514
[TBL] [Abstract][Full Text] [Related]
5. Improved In Vivo Anti-Tumor and Anti-Metastatic Effect of GnRH-III-Daunorubicin Analogs on Colorectal and Breast Carcinoma Bearing Mice.
Ranđelović I; Schuster S; Kapuvári B; Fossati G; Steinkühler C; Mező G; Tóvári J
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31557968
[TBL] [Abstract][Full Text] [Related]
6. Enhanced cellular uptake and in vitro antitumor activity of short-chain fatty acid acylated daunorubicin-GnRH-III bioconjugates.
Hegedüs R; Manea M; Orbán E; Szabó I; Kiss E; Sipos E; Halmos G; Mező G
Eur J Med Chem; 2012 Oct; 56():155-65. PubMed ID: 22967796
[TBL] [Abstract][Full Text] [Related]
7. Oxime bond-linked daunorubicin-GnRH-III bioconjugates exert antitumor activity in castration-resistant prostate cancer cells via the type I GnRH receptor.
Montagnani Marelli M; Manea M; Moretti RM; Marzagalli M; Limonta P
Int J Oncol; 2015 Jan; 46(1):243-53. PubMed ID: 25351635
[TBL] [Abstract][Full Text] [Related]
8. Enhanced In Vitro Antitumor Activity of GnRH-III-Daunorubicin Bioconjugates Influenced by Sequence Modification.
Schuster S; Biri-Kovács B; Szeder B; Buday L; Gardi J; Szabó Z; Halmos G; Mező G
Pharmaceutics; 2018 Nov; 10(4):. PubMed ID: 30423956
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and in vitro biochemical evaluation of oxime bond-linked daunorubicin-GnRH-III conjugates developed for targeted drug delivery.
Schuster S; Biri-Kovács B; Szeder B; Farkas V; Buday L; Szabó Z; Halmos G; Mező G
Beilstein J Org Chem; 2018; 14():756-771. PubMed ID: 29719573
[TBL] [Abstract][Full Text] [Related]
10. Targeting the Melanocortin 1 Receptor in Melanoma: Biological Activity of α-MSH-Peptide Conjugates.
Szabó I; Biri-Kovács B; Vári B; Ranđelović I; Vári-Mező D; Juhász É; Halmos G; Bősze S; Tóvári J; Mező G
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256168
[TBL] [Abstract][Full Text] [Related]
11. Protein expression profile of HT-29 human colon cancer cells after treatment with a cytotoxic daunorubicin-GnRH-III derivative bioconjugate.
Schreier VN; Pethő L; Orbán E; Marquardt A; Petre BA; Mező G; Manea M
PLoS One; 2014; 9(4):e94041. PubMed ID: 24718594
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro biological evaluation of daunorubicin containing GnRH-I and GnRH-II conjugates developed for tumor targeting.
Szabó I; Bősze S; Orbán E; Sipos É; Halmos G; Kovács M; Mező G
J Pept Sci; 2015 May; 21(5):426-35. PubMed ID: 25908176
[TBL] [Abstract][Full Text] [Related]
13. In-vivo antitumour effect of daunorubicin-GnRH-III derivative conjugates on colon carcinoma-bearing mice.
Manea M; Tóvári J; Tejeda M; Schulcz A; Kapuvári B; Vincze B; Mezo G
Anticancer Drugs; 2012 Jan; 23(1):90-7. PubMed ID: 21915040
[TBL] [Abstract][Full Text] [Related]
14. Characterisation of the cell and molecular biological effect of peptide-based daunorubicin conjugates developed for targeting pancreatic adenocarcinoma (PANC-1) cell line.
Szász Z; Enyedi KN; Takács A; Fekete N; Mező G; Kőhidai L; Lajkó E
Biomed Pharmacother; 2024 Apr; 173():116293. PubMed ID: 38430628
[TBL] [Abstract][Full Text] [Related]
15. Development and Biochemical Characterization of Self-Immolative Linker Containing GnRH-III-Drug Conjugates.
Schuster S; Juhász É; Halmos G; Neundorf I; Gennari C; Mező G
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563462
[TBL] [Abstract][Full Text] [Related]
16. Phage Display-Based Homing Peptide-Daunomycin Conjugates for Selective Drug Targeting to PANC-1 Pancreatic Cancer.
Dókus LE; Lajkó E; Ranđelović I; Mező D; Schlosser G; Kőhidai L; Tóvári J; Mező G
Pharmaceutics; 2020 Jun; 12(6):. PubMed ID: 32580307
[TBL] [Abstract][Full Text] [Related]
17. Targeted tumor therapy by Rubia tinctorum L.: analytical characterization of hydroxyanthraquinones and investigation of their selective cytotoxic, adhesion and migration modulator effects on melanoma cell lines (A2058 and HT168-M1).
Lajkó E; Bányai P; Zámbó Z; Kursinszki L; Szőke É; Kőhidai L
Cancer Cell Int; 2015; 15():119. PubMed ID: 26690297
[TBL] [Abstract][Full Text] [Related]
18. GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate.
Leurs U; Lajkó E; Mező G; Orbán E; Öhlschläger P; Marquardt A; Kőhidai L; Manea M
Eur J Med Chem; 2012 Jun; 52():173-83. PubMed ID: 22480495
[TBL] [Abstract][Full Text] [Related]
19. Development of novel cyclic NGR peptide-daunomycin conjugates with dual targeting property.
Tripodi AAP; Tóth S; Enyedi KN; Schlosser G; Szakács G; Mező G
Beilstein J Org Chem; 2018; 14():911-918. PubMed ID: 29765472
[TBL] [Abstract][Full Text] [Related]
20. Novel Crizotinib-GnRH Conjugates Revealed the Significance of Lysosomal Trapping in GnRH-Based Drug Delivery Systems.
Murányi J; Varga A; Gyulavári P; Pénzes K; Németh CE; Csala M; Pethő L; Csámpai A; Halmos G; Peták I; Vályi-Nagy I
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
